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Abstract 
Whereas the reduction of transfusion related
viral transmission has been a priority during the
last decade, bacterial infection transmitted by
transfusion still remains associated to a high
morbidity  and  mortality,  and  constitutes  the
most  frequent  infectious  risk  of  transfusion.
This problem especially concerns platelet con-
centrates  because  of  their  favorable  bacterial
growth  conditions.  This  review  gives  an
overview of platelet transfusion-related bacterial
contamination as well as on the different strate-
gies to reduce this problem by using either bac-
terial detection or inactivation methods.
Introduction
Reduction of transfusion related viral trans-
mission such as HIV, HBV or HCV has been a
priority  for  blood  transfusion  services.
Implementation of antibody screening followed
by  nucleic  acid  amplification  techniques
(NAT)  introduced  in  blood  donor  screening
during  the  last  decade,  have  largely  con-
tributed to this reduction.
1-5 Nevertheless, all
blood  products  remain  under  the  threat  of
emerging blood-transmitted infections (virus,
protozoans, helminths, bacteria, prions)
6 and
bacterial  transfusion  related  transmission  is
still associated to a high morbidity and mortal-
ity.
1-3,5,7-10 Platelets are especially affected by this
risk, and septic infections are most commonly
associated with platelet transfusion because of
the favorable bacterial growth conditions that
are: i) room temperature storage allowing the
growth of even small bacterial inoculums and,
ii) the biological composition of platelet con-
centrates.
3-5,9,11,12
The estimated rate of bacterial platelet con-
tamination is about 1/2,000-3,000 units (whole-
blood and apheresis-derived platelets)
1-3,5 and a
severe sepsis may be associated with one out
of 6 of contaminated platelet units transfused.
3
The risk of bacterial contamination of platelet
concentrates has been estimated to be 50-250
times higher than the combined risk of HIV,
HBV, HCV and HTLV-1/2.
9 Transfusion related
sepsis  is  often  not  recognized,  and  the  real
clinical  and  fatal  prevalence  are  probably
underestimated.
10
Platelet transfusion-related
bacterial contamination: 
some data
In the United States, bacterial contamina-
tion is considered, after transfusion errors, as
the second most common cause of death relat-
ed to transfusion.
1 As mentioned by Holme et
al., the  estimated  number  of  patients  who
received bacterial contaminated platelets per
year ranges from 2,000-4,000, resulting in 200-
600 cases of clinical sepsis, and an estimated
40-533 fatalities.
2 The death risk in the USA
has been estimated at 1/500,000 platelet con-
centrates. Between 1995 and 2001, the English
hemovigilance system reported 21 transfusion-
related bacterial contamination, leading to 6
deaths, in which 5 were attributed to platelet
contamination.
13 In France, Fournier-Wirth et
al. reported that the incidence of transfusion
related reactions due to bacterial contaminat-
ed platelets was about 1/25,000 units that was
associated with severe morbidity or even mor-
tality in about 3 cases each year in the period
1999-2003.
14 The death rate was estimated to
be one death per 200,000 distributed platelet
concentrates.
13
Platelet contamination: 
source and species of bacteria 
Several  mechanisms  may  lead  to  platelet
contamination, the major being contamination
by  the  skin  flora  at  the  site  of  punction.
3,7
Pathogens are essentially gram positive bacte-
ria like Staphylococcus aureus, coagulase neg-
ative  Staphylococci,  viridans  group  Strepto-
cocci, Bacillus spp., Corynebacteria as well as
anaerobic diphteroid gram positive bacilli such
as Propionibacterium acnes.
3,8,11 In 2004, in a
review  dealing  with  transfusion-transmitted
bacterial  infections,  Wagner  reported  that
about 56% of bacteria detected in platelet units
implicated in clinical situations of transfusion
associated sepsis were aerobic gram-positive
bacteria.
10 However, in the presence of gram
negative  organisms,  the  outcome  was  more
frequently  fatal  (60%)  when  compared  with
gram positive ones (40%). The distribution of
bacteria found in cases of transfusion related
sepsis showed Staphylococcus spp. in 42% of
cases, Escherichia coli in 9%, Bacillus spp. in
9%, Salmonella spp. in 9%, Streptococcus spp.
in 12%, Serratia spp.in 8%, Enterobacter spp.in
7%, and other organisms in 4%. The clinician
should  be  aware  that  uncommon  pathogens
might  be  encountered  in  platelet  prepara-
tions.
4,15
Infrequently, donor bacteremia may be pres-
ent  during  blood  collection,  also  leading  to
platelet contamination. In a large study evalu-
ating  the  risk  of  septic  platelet  transfusion
reactions, 23 septic transfusion reactions were
observed; 15 out of 23 reactions (62.5%) were
attributed to skin flora contamination, and 8
out of 23 (34.8%) resulted from bacteria, more
likely  associated  to  transient  donor  bac-
teremia.
16 Furthermore,  the  authors  also
showed that pooled platelet concentrates from
buffy coats have a higher bacterial contamina-
tion  rate  compared  to  apheresis  platelets.  A
total of 32,333 pooled-platelet concentrates and
of 134,159 single-donor platelet concentrates
were transfused with a rate of septic transfu-
sion  reaction  of  13/32,333  and  10/134,159,
respectively.  Thus,  they  observed  a  5.4  fold
increased rate with pooled-donor platelets.
16 In
an AABB Educational Session in Transfusion
Medicine, Hillyer et al. reported that the preva-
lence of the bacterial contamination of whole
blood derived platelets was 33.9 per 100,000
units compared to apheresis platelets whose
prevalence was 51.0 per 100,000 units.
1,5,17
The effect of bacterial screening of aphere-
sis  platelets  has  been  evaluated.  Eder  et  al.
pointed out that while septic reactions associ-
ated with platelet transfusion were estimated
to  occur  in  about  1:25,000  transfusions,  the
rate  of  contaminated  platelets  determined
after implementation of detection techniques
was  about  1:2,000  to  1:3,000.  The  authors
hypothesized that low-level contamination was
not necessarily associated with a clear clinical
response,  and  that  more  particularly,  neu-
tropenic and febrile patients were often under
antibiotic therapy that may change the clinical
picture.
18
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bacterial infection
The occurrence of a severe bacterial infec-
tion related to platelet transfusion has been
correlated to bacterial proliferation in platelet
concentrates,  and  a  bacterial  contamination
>10
5 CFU/mL has been considered as a serious
infectious  risk.
13 In  2006,  Yomtovian  et  al.
reported data from a surveillance program for
detection  of  bacterial  contamination  of
platelets in a university hospital from 1991 to
2004.
5 These data concern passive surveillance
(transfusion  reaction-triggered)  and  active
surveillance  (prospective  methods).  During
the surveillance period, 216,283 platelet units
were  transfused.  Only  one  type  of  bacterial
contamination  was  detected  by  the  passive
surveillance  method  (Pseudomonas  aerugi-
nosa,  3-day  old  random-donor  platelets).
Thirty-eight  contaminated  platelet  units  or
pools were detected by active surveillance. Six
of them were not transfused. When transfused,
the same contaminant was isolated from blood
cultures obtained from the recipient in 7 cases.
Coagulase-negative  staphylococci  was  the
most frequently isolated bacteria species fol-
lowed  by  Staphyloccocus  aureus.  Thirteen  of
the patients who received the 32 contaminated
platelets  (31  detected  by  active  surveillance
and  one  detected  by  passive  surveillance)
developed transfusion reactions. Transfusion
reaction  rate  was  significantly  higher  for
pooled random-donor platelets. Severe transfu-
sion  reactions  occurred  in  9  cases,  and  3
patients  died  of  complications,  likely  to  be
associated with the transfusion of contaminat-
ed  platelet  units  (Pseudomonas  aeruginosa,
Staphylococcus  aureus and  Serratia  marce-
scens).  Nine  of  the  13  transfusion-reactions
were  associated  with  bacterial  counts  >10
6
CFU/mL.  The  virulence  of  the  bacteria
appeared to be more important then the bacte-
rial load. However, transfusion reactions with
fever, rigors and hypotension were observed
with coagulase-negative staphylococci at bac-
terial counts as low as 10
2 CFU/mL.
5
As  bacterial  growth  increased  over  time,
platelet units, were older, the risk of high bac-
terial amounts was higher, and consequently
there was a higher risk of sepsis. In 1984, the
FDA allowed the extension of platelet storage
from five to seven days. This decision led to an
increased rate of platelet transfusion-related
infections, directly associated with the oldest
transfused units. Therefore, in 1986, the stor-
age was reduced from seven to five days.
5,19
As mentioned above, severity of the clinical
manifestations  related  to  contaminated
platelet units are determined by quantitative/
qualitative  parameters  (number  of  CFU
infused, type of bacteria, rate of proliferation,
latency phase). Whereas in some cases fever
and chills are present during the transfusion,
in many cases the patient remains asympto-
matic. In the symptomatic recipient, fever and
chills may be observed within two hours after
the start of transfusions. Hypotension, nausea,
vomiting, diarrhea, oliguria, respiratory symp-
toms and shock may be observed. The severity
of a septic transfusion reaction also depends
on  the  patient’s  characteristics  and  may  be
more  severe  in  immunocompromised
patients.
1,5,8
In order to reduce the risk of post-transfu-
sion  sepsis  from  bacterial  contaminated
platelets, various procedures have been imple-
mented:  improved  donor  selection,  single-
donor apheresis platelets, reduction of the con-
tamination risk of the phlebotomy process by
optimal skin disinfection procedures and the
removal of the first 10-30 mL of the initial col-
lected blood, storage time limitation, bacterial
detection and inactivation methods.
1,3,7 Indeed,
as the major cause of platelet contamination is
the normal skin flora at the site of punction
3,7
optimal  skin  disinfection  may  significantly
reduce contamination. However, when the col-
lection needle enters the skin, bacteria may be
introduced into blood. Different studies have
suggested that the removal of the first aliquot
of the initial collected blood may reduce the
risk of bacterial contamination in blood dona-
tion.
1,20,21
Methods for detection of 
bacterial contamination of
platelets: culture methods
When  compared  with  bacterial  detection
methods, surrogate tests such as pH measure-
ment, glucose level determination or Gram’s
stain coloration have been shown to have low
sensitivity and thus, can not be recommended.
1
Two methods have been approved by the FDA
for the detection of bacterial contamination in
platelets.  The  first  one  is  BacT/ALERT
®
(BioMérieux Inc.), an automated colorimetric
blood culture method, based on the detection
of  carbon  dioxide  produced  by  proliferating
microorganisms, which allows the detection of
both aerobic and anaerobic bacteria as well as
yeasts  and  fungus.
4,8,10 The  second  one  is
eBDS
® (Pall Corporation), an enhanced bacte-
rial detection method based on the measure-
ments of oxygen consumption by bacteria in
the  milieu.
4,14 A  comparison  between  the
advantages and disadvantages of both methods
is presented in Table 1 [adapted from (4)].
The Verax Biomedical Platelet PGD
® Test for
Bacterial detection (Verax Biomedical, Inc.) is
a new rapid and qualitative immunoassay test
for the detection of aerobic and anaerobic bac-
teria in leukocyte reduced apheresis platelets.
However, in the absence of sufficient data, a
comparison  between  this  method  and  both
BacT/ALERT
® and Pall eBDS
® is not possible.
BacT/ALERT
® is an automated colorimetric
blood culture method allowing the detection of
both aerobic and anaerobic bacteria as well as
yeasts and fungal microorganisms, in two cul-
ture bottles, one for aerobic and one for anaer-
obic pathogens. The bottom of the bottles con-
tains  a  pH  sensitive  liquid  sensor  which
changes its color according to the amounts of
CO2 released. Whereas bacteria produce CO2,
yeasts  and  fungi  are  high  acid-producing
organisms.  Inoculation  of  approximately  7.5
mL of the platelet sample is necessary for each
bottle, and is performed 24 hours after collec-
tion. The bottles are then incubated at 37°C.
The CO2production is correlated with the alter-
ation of the reflection of the light on the sen-
sor. When the color changes, an alarm is set
off. The bottles are continuously analyzed and
tested for up to 5-7 days. This system has been
used for routine detection of platelet bacterial
contamination  in  the  Netherlands,  Belgium
and Wales for several years.
4,8,10
In  2002,  McDonald  et  al. reported  data
resulting  from  the  evaluation  of  the
BacT/ALERT
® system  after  inoculation,  in  2-
day old apheresis platelets, of different bacter-
ial species (9 gram positive, 5 gram negative)
and one fungal microorganism at a concentra-
tion of 10-100 CFU/mL. The results were com-
pared  to  thioglycollate  broth  cultures.  The
mean time for the bacterial detection ranged
between 9.1-48.1 hours, with the exception of
Propionibacterium  acnes (89-177.6  hours).
22
Analogous results were obtained by Brecher et
al.,
19 who  also  confirmed  the  large  delay
required  for  detection  of  Propionibacterium
acnes.  However,  it  is  important  to  note  that
anaerobic Propionibacterium acnes has a poor
growth in the aerobic platelet conditions, and
that its clinical relevance is all but clear.
2,7,19,22
As bacterial load may be very low in freshly col-
lected platelets (<10 CFU/mL sometimes even
<1 CFU/mL)
10 a storage period ≥24 hours is
required  before  inoculation,
10,19,22 in  order  to
allow bacterial growth and to avoid false nega-
tive results.
To better assess the prevalence and nature
of  bacterial  contamination  of  pooled  and
apheresis  platelets,  the  GERMS  (German
Evaluation  of  Regular  Monitoring  Study)
Group of the Red Cross Transfusion Services
initiated  a  prospective  multimember  study
including  9  different  centers.  The  results  of
this  study  have  been  reported  by  Schrezen-
meier et al. in 2007. The BacT/ALERT
® method
was  used  to  analyze  52,243  platelet  concen-
trates  (15,198  collected  by  apheresis  and
37,045  pooled  platelets).  Of  the  282  platelet
concentrates  with  a  first  positive  culture,  a
Article
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bacteria was identified in 135. Among these
135 concentrates, 37 were confirmed positive
by second cultures. There was no significant
difference  in  the  rate  of  confirmed  positive
platelet  concentrates  between  apheresis  and
pooled  platelets.  Among  these  37  confirmed
positive  platelet  concentrates,  most  bacteria
isolated  were  skin  flora  bacteria.  Propioni-
bacterium acnes was found in 54% of them,
and staphylococci species in 43% of them, with
Staphylococcus  epidermidis in  most  of  the
cases. Serratia marcescens and Staphylococcus
aureus, which are potentially pathogenic bac-
teria, were isolated respectively in one plasma
pooled platelet concentrate and in one aphere-
sis  platelet  concentrate.  This  study  demon-
strated that a large scale routine screening of
platelets  prepared  by  different  blood  centers
was feasible. However, the authors observed
that such a screening did not allow the preven-
tion of the transfusion of contaminated units
because of the interval of time needed after
inoculation and the detection of the contami-
nant.  In  addition,  the  risk  of  false  negative
results was not eliminated by this approach.
7
Two  cases  of  life-threatening  sepsis  due  to
Bacillus  cereus contamination  despite  the
BacT/ALERT
® detection  method  were
described  by  te  Boekhorst  et  al. in  the
Netherlands.
15
In another important multi-center German
study,  comparing  three  bacterial  detection
methods under routine conditions, Schmidt et
al.  reported  2  severe  transfusion  reactions
after transfusion of 2 split apheresis platelet
concentrates  contaminated  with  Klebsiella
pneumoniae,  despite  a  negative  screening
with both BacT/ALERT
® and Pall eBDS
® detec-
tion methods.
4
In  the  Netherlands,  te  Boekhorst  et  al.
reported  their  experience  with  the
BacT/ALERT
® system  implemented  in  their
center  for  routine  bacterial  screening  of
platelets in October 2001. Over a period of two
years, 28,104 pooled platelets were screened:
203 of them were detected as being contami-
nated  and  125  out  of  203  had  already  been
released at the time of the detection. Ninety
percent of them were already transfused. No
adverse reactions such as fever, hypotension,
or  other  unexplained  clinical  deterioration,
were observed after a contaminated transfu-
sion. Early detection (≤48 hours) of bacterial
contamination with microbiological confirma-
tion was possible in 59 concentrates, and 48 of
them could be recalled. For late detection (>48
hours), only 33 of 125 contaminated concen-
trates  could  be  recalled.  The  authors  also
observed that 68% of the BacT/ALERT
® screen-
ing cultures became positive after an incuba-
tion of 48 hours.
15 They noted that this low rate
was  in  contrast  with  several  studies  that
showed  higher  rates  of  bacterial  detection
after an incubation of 48 hours. For instance,
Wagner and Robinette showed that deliberate
bacterial inoculation in platelet concentrates
could be detected after 48 hours in all of the
cases.
15,23 Brecher et al. reported detection of
inoculated  microorganisms  in  apheresis
platelet  units  (with  the  exception  of
Propionibacterium acnes) in a mean time of
9.3-18.9 hours (10 CFU/mL) or 8.7-18.2 hours
(100 CFU/mL).
15,24 Te Boekhorst et al. pointed
out  the  fact  that  this  difference  could  be
explained by a presumably very low bacterial
load in their platelet concentrates compared to
the experimental inoculation load.
15
As  previously  mentioned,  Pall  eBDS
® is  a
culture method system based on the bacterial
consumption of oxygen and only allows detec-
tion of aerobic and facultative anaerobic bacte-
ria. Twenty-four hours after collection, 3 mL of
the platelet concentrate are filtered in order to
remove platelets and leukocytes, and then are
inoculated into a sampling bag. The pouch con-
tains  two  tablets:  i)  a  sodium  polyanethol
sulphonate dissolvable tablet that reduces the
natural inhibitors of bacterial growth and also
acts as a platelet aggregating agent in order to
lower platelet competitive consumption of O2
and,  ii)  a  trypticase  soy  medium-containing
tablet that enhances the sensitivity by provid-
ing nutrients for bacterial growth. The sample
is incubated for 24 hours at 35°C, and the level
of O2 is measured.
2,4,10,14
Like BacT/ALERT
®, the Pall eBDS
® in vitro
sensitivity was determined to be between 1-10
CFU/mL. Moreover, in order to reduce the risk
of false negative results, a period of storage
≥24 hours has been advocated.
10 The perform-
ance of the Pall eBDS
® was evaluated in four
test sites after inoculation 1-15 CFU/mL of 10
different bacterial species known to be associ-
ated with fatal platelet transfusion related out-
come.  The  inoculated  samples  were  trans-
ferred in Pall eBDS
® bags immediately after
inoculation or after a 24 hour storage at 22°C.
The results were reported by Holme et al. who
showed that all samples incubated 24 hours
after inoculation were detected as being con-
taminated (100% sensitivity) and no false pos-
itives  were  obtained  with  713  uninoculated
platelets.
2
Fournier-Wirth  et  al. reported  the  results
from a study performed in 3 transfusion cen-
ters  in  France  on  pooled  and  apheresis
platelets. The aim of this study was to evaluate
the ability of the Pall eBDS
® system to detect
bacterial  contamination  after  a  reduction  of
the  incubation  time.  The  results  were  com-
pared with the BacT/ALERT
® system, consid-
ered in this study as a reference. Low levels (5-
50 CFU/mL) of 5 different strains of bacteria
were  inoculated  in  the  platelet  units.  The
platelets were stored at 22°C, 24 hours before
Article
Table 1. A comparison of the advantages and disadvantages of BacT/ALERT
® and Pall eBDS
®, according to the data reported by
Schmidt et al.
4 The sensitivity, efficiency and manageability of BacT/ALERT
® and Pall eBDS
® were compared in a multicenter-study
carried out in 4 German centers. It concerned 6,307 pooled platelets and 4,730 apheresis.
Pall eBDS
® BacT/ALERT
®
Advantages Sensitivity* Sensitivity*
Good specificity** Detection of aerobic and anaerobic bacteria, yeasts, and fungal microorganisms
Closed system The bottles are continuously analyzed and tested, for up to 5-7 days
Easy and quick handling Easy and quick handling
Disadvantages Detection of aerobic and only facultative  Specificity*
anaerobic bacteria
A punctual measure in time whereas platelets Open system
may be transfused until 5 days after collection
Platelets may be released before the time 
of detection
*This evaluation revealed a better sensitivity for the BacT/ALERT
® system, identifying 4 positive samples that were missed with the Pall eBDS
®. **The specificity of BacT/ALERT
® (0.25%, 28 out of 11,037
tested samples) was significantly lower compared to Pall eBDS
® (0.03%, 3 out of 11,037 tested samples).[Hematology Reviews 2009; 1:e5] [page 25]
sampling. Time to detection ranged between 8-
17 hours. Sixty-three contaminated bags were
incubated for 18 and 24 hours at 35°C. Sixty-
one out of 63 (96.82%) were detected as being
positive after 18 hours and all at 24 hours. The
O2 level of the 2 samples negative at 18 hours
(contaminated with Bacillus cereus) was near
the detection threshold. However, the negative
samples detected an O2level >17%. There were
no  false  positive  results  (100%  specificity).
They  conclude  that  the  Pall  eBDS
® method
allows testing of platelet concentrates 42 hours
after collection similarly to the Bac/T ALERT
®
system.
14
The limitation of the Pall eBDS
® detection
system concerns the failure to detect anaero-
bic  bacteria.  However,  anaerobic  organisms
are only rarely associated with fatal infection
after platelet transfusions.
2,10,14
The sensitivity, efficiency and manageabili-
ty of BacT/ALERT
® and Pall eBDS
® were com-
pared in a multi-center study carried out in 4
German  centers.
4 It  concerned  6,307  pooled
platelets  and  4,730  apheresis  platelets.  A
microbiological reference laboratory evaluated
all  initially  positive  results.  This  evaluation
revealed  a  better  sensitivity  for  the
BacT/ALERT
® system,  identifying  4  positive
samples that were missed with the Pall eBDS
®.
However,  the  enhanced  sensitivity  of  the
BacT/ALERT
® system was offset by a reduced
specificity which was defined in this study as
the number of false-positive test samples. The
specificity of BacT/ALERT
® (0.25%, 28 out of
11,037 tested samples) was significantly lower
compared to Pall eBDS
® (0.03%, 3 out of 11,037
tested samples). However, the authors conclud-
ed  that  this  reduced  specificity  might  be
acceptable. BacT/ALERT
® detected 32 positive
samples with microbiological confirmation out
of 11,037 and Pall eBDS
® detected one positive
sample. These samples were considered as ini-
tially positive. However, these initially positive
results were not confirmed by the analysis of a
second sample, either from the satellite bag, or
from the original platelet bag, or from a related
erythrocyte bag (in case of pooled platelet). A
possible  explanation  may  be  an  exogenous
contamination during the test procedure. For
that reason, Pall eBDS
® which is a closed sys-
tem may be preferable to BacT/ALERT
® which
is an open one.
Detection of bacterial 
contamination with molecular
based methods
In order to provide more rapid, sensitive and
highly specific results, molecular technologies,
based on the detection of ribosomal RNA of a
wide variety of bacteria in a platelet contami-
nated  sample  containing  1-10  CFU/mL,  have
also been evaluated.
10,25
In  1999,  Chaney  et  al. described  a  new
process allowing the targeting of bacterial ribo-
somal RNA in five steps: i) cell lyses leading to
the release of ribosomal RNA, ii) hybridization
of  bacterial  ribosomal  RNA  with  biotin  and
ruthenium-labeled oligonucleotide probe pairs,
iii) capture of the labeled ribosomal RNA with
streptavidin-coated magnetic beads, and then
iv) setting of the RNA on an electrode surface
and detection of ruthenium-labeled ribosomal
RNA by application of voltage, v) followed by
the generation of an electrochemiluminescent
signal. By this approach, the authors were able
to  obtain  a  linear  relationship  between  the
electrochemiluminescent  signal  representing
the ribosomal RNA level with the number of
CFU/mL.
26,27 However,  even  if  this  method
appeared to be suitable for routine application,
its sensitivity was not sufficient. It only allowed
the detection of approximately 10
5 CFU/mL.
27
Störmer et al. recently published the results
of a study evaluating bacterial spreading in the
different blood components infected by inocu-
lation of Klebsiella pneumoniae and Staphylo-
coccus epidermidis. Using RT-PCR, Klebsiella
pneumoniae was detected in platelet concen-
trates  immediately  after  its  preparation.
Staphylococcus epidermidis, which has a slow-
er growth, was only detected 24 hours after the
whole  separation  process.  The  authors  con-
cluded that a 24 hour storage was necessary
before processing to RT-PCR.
17
Even if molecular based technologies repre-
sent a high potential for bacterial detection,
their applicability in the context of detection of
bacteria in platelet concentrates has not yet
been demonstrated. 
Furthermore, their use is limited by the cost,
complexity of use and, more critically, by the
availability  of  bacterial-derived  nucleic  acid
amplification reagents.
25
In  a  review  of  the  literature  published  in
2004 about how to improve the bacteriological
safety of platelet transfusions, Blajchman et al,
pointed out that all bacterial contaminants can-
not currently be detected by molecular methods
and that it is not clear if bacterial DNA or rRNA
is the most appropriate test marker.
28
One of the most important practical prob-
lems with the use of broad-range PCR is the
contamination of the assay by exogenous bac-
terial  DNA  of  the  nucleotide  amplification
reagents, particularly of the bacterial derived
enzymes  and  the  bacterial  DNA  sequences
commonly  found  in  human  blood.  Moreover,
the detection of a minor amount of bacterial
DNA among a high quantity of human DNA
may also constitute a problem.
25 To our knowl-
edge, methods based on bacterial amplification
techniques are not currently employed in rou-
tine screening of platelet concentrates.
Pathogen inactivation
Pathogen reduction technologies allow inac-
tivation of viruses and bacteria in contaminat-
ed platelet concentrates. Two main different
approaches have been described.
Psoralen based method
The  INTERCEPT  blood  system
® (Cerus
Corporation) uses amotosalen which is a syn-
thetic psoralen, an organic compound found in
fruit  and  vegetables  like  limes  and  celery.
29
Amotosalen  compound  has  the  potential  to
penetrate into cells, to cross the nuclear mem-
brane, and to reversibly intercalate into helical
regions of nucleic acid. Exposure to a long-
wave-length  ultraviolet  light  (UVA,  320-400
nm) leads to covalent crosslinks between amo-
tosalen molecules and pyrimidine bases, block-
ing  DNA  and  RNA  replication  (cells  and
pathogens with nucleic acid genomes). After
light  treatment,  the  residual  amotosalen  as
well as its metabolites are removed by a com-
pound  adsorbing  device  during  a  prolonged
incubation. Platelets do not have nuclei and
are not affected by psoralens.
29-35 In 2005, Lin et
al. reported results that advocate the efficien-
cy of such an approach for virus inactivation.
The authors studied 10 different families of
viruses  including:  i)  the  most  relevant  for
blood  transfusion  like  HIV-1,  HIV-2,  HBV,
HTLV-1, HTLV-2 or CMV, ii) viruses of emerg-
ing  interest  like  parvovirus  B19,  West  Nile
virus,  severe  acute  respiratory  syndrome-
human coronavirus, and vaccinia virus, and,
iii) model viruses like duck hepatitis virus (an
HBV model), bovine viral diarrhea virus (an
HCV model), bluetongue virus, feline conjunc-
tivitis virus, simian adenovirus 15 and porcine
parvovirus. According to the FDA, the process
was defined as being effective if the pathogen
load was reduced by 6-10 logs. The results of
this study showed a significant log reduction
of enveloped viruses that were uniformly sen-
sitive  to  inactivation.  The  non-enveloped
viruses showed a variable sensitivity to inacti-
vation. Parvovirus B19 and human adenovirus
5 were inactivated to the limit of detection,
whereas the other non-enveloped viruses were
resistant to inactivation.
31 In 2006, Singh et al.
reported that the photochemical treatment of
plasma with amotosalen inactivates high lev-
els  of  gram  positive  (Streptococcus  epider-
midis) and gram negative (Klebisella pneumo-
niae,  Yersinia  enterocolitica)  bacterias.  They
determined  that  the  mean  log  reductions
achieved were >7.3 for Streptococcus epider-
midis and Yersinia enterocolitica and >7.4 for
Klebisella  pneumoniae.  Photochemical  treat-
ment was also efficient at high initial titers on
spirochetes  with  mean-reductions  >5.9  for
Treponema  pallidum and  >10.6  for  Borrelia
burgdorferi and on protozoa with mean-reduc-
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tion >6.9 for Plasmodium falciparum, >5 for
Trypanosomia  cruzi and  >5.3  for  Bancrofti
microti. They also showed the maintenance of
clotting  time  and  plasma  coagulation  factor
activity  after  photochemical  treatment.
35,36
Genomic DNA in leukocytes is modified by pso-
ralens that are able to inactivate more than 5.4
logs of T lymphocytes and to disrupt more base
pairs  (1:83)  than  gamma-irradiation
(1:37,000).
35 Grass et al. reported that a dose of
0.05 ʼmol/L of amotosalen, which is 3,000 fold
lower than the dose used for viruses and bacte-
ria inactivation, was sufficient to inactivate T
lymphocytes  after  1  J/cm
2 of  UVA  illumina-
tion.
33 The extreme sensitivity of the T lympho-
cytes to psoralens suggests that this treatment
has the potential to reduce the incidence of
leukocyte mediated adverse immune reactions
associated with platelet transfusion like trans-
fusion  associated  graft-versus-host  disease
and  platelet  related  febrile  non-hemolytic
transfusion reaction.
12,33,37 Platelet concentrates
treated with psoralens seem to have a compa-
rable  in  vitro function  compared  with  non-
treated platelet concentrates and their viability
seem to be conserved.
32,38-40
In  2004,  McCullough  et  al. reported  the
results  of  the  SPRINT  trial  which  was  a
prospective,  randomized,  controlled,  double-
blind parallel group phase III study carried out
to evaluate the efficacy and the safety of photo-
chemical  treated  with  amotosalen  platelets
compared  with  non-treated  control  platelets
collected  by  apheresis.  The  efficacy  was
defined by prevention and treatment of signif-
icant  bleeding:  proportion  of  patients  with
WHO grade 2 bleeding as primary efficacy end
point,  the  proportion  with  WHO  grade  3-4
bleeding,  number  of  days  of  WHO  grade  2
bleeding, one hour and 24 hour platelet count
increments, corrected count increments, num-
ber of days to next platelet transfusion, num-
ber of platelet transfusion incidence of platelet
refractoriness and number of erythrocyte con-
centrate  transfusions  as  secondary  efficacy
end points. Safety end points were defined by
the number of platelet transfusion reactions,
development of antibody to potential amotos-
alen neoantigens and overall safety. The study
included 671 thrombocytopenic patients need-
ing platelet transfusion support: 318 received
photochemical  treated  platelets,  327  control
platelets  and  26  of  them  did  not  require
platelet  transfusion.  This  trial  showed  that
whereas the hemostatic effect of both photo-
chemical  treated  and  control  platelets  were
comparable,  the  transfusion  of  treated
platelets was associated with a lower platelet
count increment after transfusion. This lower
platelet  count  increment  could  partly  be
explained by the lower mean platelet dose in
the photochemical treated group (3.7ￗ10
11 vs.
4ￗ10
11 in the control group; p<0.01) and by a
greater proportion of treated platelet that con-
tained  <3ￗ10
11 platelets.  Thus,  patients  who
received  photochemical  treated  platelets
received more platelet transfusions and had a
shorter  interval  between  transfusion  than
patients who received conventional platelets.
41
Studies performed in animals and humans
reported no evidence for a toxicity of psoralen
treatment.
34,40,42 Webert et al. related acute toxi-
city with amotosalen after UVA activation in
rats with a lethal threshold dose of 150 mg/kg.
In  dogs,  central  nervous  system  alterations
were  observed  after  a  threshold  dose  of 
30  mg/kg.  These  doses  were  respectively
150,000 and 30,000 fold higher than the dose
used for pathogen inactivation. Reproductive
toxicity, determined by histological rather than
functional  evaluation,  was  observed  at  a
threshold of 0.35 mg/kg, which was 350 times
higher than the dose used for pathogen inacti-
vation.  Moreover,  all  substances  used  for
pathogen  inactivation  are  water  soluble  and
rapidly excreted avoiding the bioaccumulation
of trace amounts in treated blood products.
35 In
addition,  transfusion  of  platelets  or  plasma
treated  with  this  method  did  not  appear  to
induce adverse immunological response when
evaluated  by  searching  the  presence  of
neoantigens.
29,35,41
In 2005, Lin et al. evaluated the potential of
photochemical treatment with amotosalen to
create  neoantigens.  They  quantified  the
amounts  of  residual  amotosalen  and  photo-
products  in  photochemical  treated  platelets
and plasma. Patients’ serum samples from 7
Phase III clinical trials including 523 patients
who received more than 8,000 units of treated
platelets or plasma, were assayed by enzyme
linked immunsorbent assay (ELISA) for anti-
bodies to amotosalen neoantigens. The results
indicated that no neonatigens were detected
by ELISA after photochemical treatment with
amotosalen.
29
Riboflavin based method
The  Mirasol
® PRT  (Navigant  Biotechnolo-
gies Inc.) system is similar to the psoralen-
based method, but uses a different photo-sen-
sitizer, riboflavin (vitamin B2) instead of pso-
ralen. Riboflavin is a natural component found
in food (milk, beer, eggs, yeasts, leafy vegeta-
bles),  and  is  classified  as  a  “Generally-
Regarded-As-Safe” compound by the FDA.
30,43,44
Riboflavin  interacts  with  nucleic  acids  after
exposure to UV light (280-360 nm) and causes
irreversible damage to DNA/RNA (direct elec-
tron transfer, production of singlet oxygen and
production of hydrogen peroxide leading to the
formation of hydroxyl radicals). A compound
adsorbing device removal process for residual
riboflavine  metabolites  may  not  be  neces-
sary.
30,43 Perez-Pujol  et  al. have  studied  the
impact of this method on the functional and
biochemical characteristics of platelet concen-
trates.  They  observed,  with  flow  cytometry
studies, the same changes in treated and non-
treated platelets, without modification of FvW,
fibrinogen  and  FVa  levels  after  five  days  of
storage.  They  also  showed  that  treated
platelets have adhesive and cohesive functions
similar to non-treated platelets.
45 Ruane et al.
have shown that the Mirasol
® PRT system is
able  to  inactivate  viruses  and  bacteria  in
platelet  concentrates.  They  observed  signifi-
cant log reductions for cell-associated and cell-
free HIV, West Nile virus, porcine parvovirus,
and for gram positive and gram negative bacte-
ria  such  as  Staphylococcus  epidermidis or
Escherichia coli. The authors noted that the
platelet  pH  and  the  lactate  production  rate
were, as suggested by the literature data, pre-
dictive of recoveries in 50.8-59.8%. Therefore,
they used platelet pH and lactate production
rate as platelet quality indicators and conclud-
ed  that  platelet  cell  quality  was  maintained
after treatment and during storage.
46 Goodrich
et al. reviewed Mirasol
®PRT performances and
confirmed that this system was able to inacti-
vate viruses and various bacteria species such
as Staphylococcus epidermidis, Staphylococcus
aureus, Escherichia coli, Pseudomonas aerugi-
nosa,  Bacillus  cereus,  Serratia  marcescens.
These data suggested a significant reduction
of the risk of platelet related bacteria transmis-
sion.
16,44,47 Kumar et  al. showed  an  increased
genomic DNA degradation in leukocytes and
bacteria  after  riboflavin  and  UV  light  treat-
ment,
48also suggesting that Mirasol
®PRT tech-
nology may be an alternative to gamma irradi-
ation to prevent transfusion associated graft-
versus-host disease.
43
In December 2007, Klein et al. reported in a
consensus conference about pathogen inactiva-
tion (Toronto, March 2007) that pathogen inac-
tivation  methods  should  be  implemented  as
soon as feasible and safe methods to inactivate
a broad spectrum of infectious agents are avail-
able.
12 The authors established a list of existing
criteria and procedures that should be changed
in case of implementation of pathogen inactiva-
tion such as the suppression of screening tests
for: i) Treponema pallidum; ii) agents of low
infectious titer and destroyed early by pathogen
inactivation like West Nile virus, which is actu-
ally systematically tested in the US and Canada;
iii) agents that are sensitive to pathogen inacti-
vation for which redundant safety measures are
taken (CMV, HTLV, HbsAg and those for which
the  methods  of  detection  available  nowadays
lack specificity and sensitivity like those used to
detect bacteria). Moreover, gamma irradiation
of blood components performed to eliminate the
risk of transfusion associated graft-versus-host
disease could be eliminated. The authors con-
clude that an agent that is known to be ade-
quately  inactivated  by  these  technologies
should not require screening tests unless of an
unusually high infectious titer.
12
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Towards a change of paradigm:
inactivation versus detection
The ability of pathogen reduction technolo-
gies to inactivate a broad spectrum of organ-
isms (virus, fungus, bacteria, parasites) is one
of  the  most  convenient  answers  to  face  the
rapidly evolving epidemiological environment
as well as the continuous appearance of new
pathogens. Multiple different factors effective-
ly contribute to the occurrence of emerging or
re-emerging  infectious  agents:  migration,
travel,  conflicts,  climatic  changes,  demogra-
phy, and numerous less trivial factors like for
instance pet trade through e-business.
6,49-52 The
occurrence of pathogens with a strong epidem-
ic potential, and/or with high prevalence, as
well as the diversity of existing pathogens that
are not systematically detected using standard
screening approaches, strongly argue for the
introduction of inactivation procedures rather
than continuously introducing new biological
tests, each being characterized by its own sen-
sitivity and specificity.
Conclusions
The bacterial transmission still constitutes
a significant problem in transfusion medicine.
Because  of  their  favorable  bacterial  growth
conditions (storage at room temperature, bio-
logical  composition)  platelets  are  of  special
concern. As shown in this review, data avail-
able suggest that bacterial detection with the
technology available nowadays may present a
false sense of security. To our knowledge, there
is no recently approved “revolutionary” bacter-
ial detection technology that can dramatically
and definitively make platelet transfusion safe.
By contrast, pathogen inactivation has demon-
strated its efficiency. However, long-term stud-
ies are still needed to demonstrate the safety
of this approach. Newer pathogen inactivation
technologies are currently under development,
like CryoFacet red blood cell and platelet tech-
nology using counterflow elutriation to remove
infectious agents in plasma, followed by ozona-
tion and treatment with germicidale UV before
releasing.
35 Other approaches such as “glyco-
engineering”  the  platelets  in  order  to  allow
their cold storage and rapid bacterial detection
(at the moment of release) are under develop-
ment.
35,53
In  summary,  this  review  describes  recent
technologies that may be used to make platelet
transfusion safe, with a particular emphasis
on the prevention of bacterial contamination.
Based on the literature review, and more par-
ticularly  for  people  who  are  not  directly
involved in the development and/or implemen-
tation  of  these  particular  technologies  (like
the  authors  of  this  review),  the  choice
between all these different approaches is very
difficult.
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